Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.

@article{Brauer2013IdentificationAA,
  title={Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.},
  author={Matthew J. Brauer and Guanglei Zhuang and Maike Schmidt and Jenny Yao and Xiumin Wu and Joshua S. Kaminker and Stefanie S Jurinka and Ganesh Kolumam and Alicia S. Chung and Adrian M. Jubb and Zora Modrusan and Tomoko Ozawa and C. David James and Heidi Phillips and Benjamin Haley and Rachel N W Tam and Anne C Clermont and J. H. Cheng and Sherry X. Yang and Sandra M Swain and Daniel L. T. Chen and Stefan J. Scherer and Hartmut Koeppen and Ru-Fang Yeh and Peng Yue and Jean Philippe Stephan and Priti Hegde and Napoleone M. A. Ferrara and Mallika Singh and Carlos Bais},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 13},
  pages={3681-92}
}
PURPOSE The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in patients. EXPERIMENTAL DESIGN Surrogate markers of VEGF inhibition [VEGF-dependent genes or VEGF-dependent vasculature (VDV)] were identified by profiling gene expression changes induced in response to VEGF blockade in preclinical tumor models and in human biopsies from patients treated… CONTINUE READING

From This Paper

Topics from this paper.
14 Citations
53 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Similar Papers

Loading similar papers…